688062 迈威生物-U
已收盘 11-06 15:00:00
资讯
新帖
简况
迈威生物（688062）11月5日主力资金净卖出202.65万元
证券之星 · 11-06 08:20
迈威生物（688062）11月5日主力资金净卖出202.65万元
迈威生物（688062）10月23日主力资金净卖出680.54万元
证券之星 · 10-24
迈威生物（688062）10月23日主力资金净卖出680.54万元
迈威生物（688062）披露9MW2821在ESMO大会以口头报告形式公布II期临床数据，10月19日股价上涨1.21%
证券之星 · 10-19
迈威生物（688062）披露9MW2821在ESMO大会以口头报告形式公布II期临床数据，10月19日股价上涨1.21%
近两千亿解禁潮：首发股东浮盈翻倍，定增机构普遍亏损
东方财富网 · 10-19
近两千亿解禁潮：首发股东浮盈翻倍，定增机构普遍亏损
迈威生物（688062）10月13日主力资金净卖出775.58万元
证券之星 · 10-14
迈威生物（688062）10月13日主力资金净卖出775.58万元
迈威生物（688062）10月8日主力资金净买入221.75万元
证券之星 · 10-09
迈威生物（688062）10月8日主力资金净买入221.75万元
迈威生物(688062.SH)子公司联威创元拟引入投资人 旨在推动创新药业务发展
智通财经 · 09-28
迈威生物(688062.SH)子公司联威创元拟引入投资人 旨在推动创新药业务发展
迈威生物：拟向联威创元增资8.25亿元并转让TCE项目资产
格隆汇 · 09-28
迈威生物：拟向联威创元增资8.25亿元并转让TCE项目资产
迈威生物（688062）披露将参加科创板2026年半年度创新药行业集体业绩说明会，9月1日股价下跌1.62%
证券之星 · 09-01
迈威生物（688062）披露将参加科创板2026年半年度创新药行业集体业绩说明会，9月1日股价下跌1.62%
迈威生物（688062）2026年中报简析：营收上升亏损收窄
证券之星 · 09-01
迈威生物（688062）2026年中报简析：营收上升亏损收窄
迈威生物(688062)6月30日股东户数1.85万户，较上期减少2.76%
证券之星 · 08-30
迈威生物(688062)6月30日股东户数1.85万户，较上期减少2.76%
港股午评|恒生指数早盘跌0.63% CRO概念继续走高
智通财经 · 08-11
港股午评|恒生指数早盘跌0.63% CRO概念继续走高
每周股票复盘：迈威生物（688062）9MW5211注射液获临床试验批准
证券之星 · 08-02
每周股票复盘：迈威生物（688062）9MW5211注射液获临床试验批准
迈威生物-U：9MW5211注射液临床试验申请获国家药监局批准
投资观察 · 07-31
迈威生物-U：9MW5211注射液临床试验申请获国家药监局批准
迈威生物-U：9MW5211注射液临床试验申请获NMPA批准
美股速递 · 07-31
迈威生物-U：9MW5211注射液临床试验申请获NMPA批准
每周股票复盘：迈威生物（688062）9MW5211注射液获准开展白癜风临床试验
证券之星 · 07-19
每周股票复盘：迈威生物（688062）9MW5211注射液获准开展白癜风临床试验
迈威生物-U新药9MW5211注射液临床试验申请获国家药监局批准
美股速递 · 07-15
迈威生物-U新药9MW5211注射液临床试验申请获国家药监局批准
每周股票复盘：迈威生物（688062）9MW5211注射液获批T1DM临床试验
证券之星 · 07-12
每周股票复盘：迈威生物（688062）9MW5211注射液获批T1DM临床试验
迈威生物-U新药9MW5211注射液临床试验申请获国家药监局批准
美股速递 · 07-07
迈威生物-U新药9MW5211注射液临床试验申请获国家药监局批准
迈威生物(688062.SH)：9MW5211注射液临床试验申请获批准
智通财经 · 07-07
迈威生物(688062.SH)：9MW5211注射液临床试验申请获批准
加载更多
公司概况
公司名称：
迈威(上海)生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2022-01-18
主营业务：
迈威(上海)生物科技股份有限公司的主营业务是研发、生产以及销售创新型药物和生物类似药。公司的主要产品是抗体、ADC药物、重组蛋白、小分子化学药。截至本报告披露日，公司拥有15个处于临床研究或上市阶段的重点品种，其中4个产品已获批上市，1个品种在境内生产药品注册上市许可申请审评中；2026年以来，共有3个品种获得国内外9项临床试验准入。
发行价格：
34.80
{"stockData":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"迈威生物-U","latestPrice":22.08,"timestamp":1793948400000,"preClose":22.67,"halted":0,"volume":6705785,"delay":0,"changeRate":-0.026,"floatShares":400000000,"shares":447000000,"eps":-2.3507,"marketStatus":"已收盘","change":-0.59,"latestTime":"11-06 15:00:00","open":21.73,"high":23.13,"low":21.67,"amount":150000000,"amplitude":0.0644,"askPrice":22.09,"askSize":10,"bidPrice":22.08,"bidSize":59,"shortable":0,"etf":0,"ttmEps":-2.3507,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794187800000},"marketStatusCode":5,"adr":0,"adjPreClose":22.67,"symbolType":"stock_kcb","openAndCloseTimeList":[[1793928600000,1793935800000],[1793941200000,1793948400000]],"highLimit":24.94,"lowLimit":20.4,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":446730200,"isCdr":false,"pbRate":13.77,"roa":"--","roe":"--","epsLYR":-2.43,"committee":0.528336,"marketValue":9864000000,"turnoverRate":0.0168,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-11-09。","afterMarket":{"amount":55597.44,"volume":2518,"close":22.08,"buyVolume":0,"sellVolume":3482,"time":1793950437746,"indexStatus":"已收盘 11-06 15:30:00","preClose":22.67},"hkstockBrief":{"symbol":"02493","market":"HK","secType":"STK","nameCN":"迈威生物-B","latestPrice":18.15,"timestamp":1793952530739,"preClose":18.51,"halted":0,"volume":109800,"delay":0,"premium":"-30.06"},"floatMarketCap":8823000000},"requestUrl":"/m/hq/s/688062","defaultTab":"news","newsList":[{"id":"2681817308","title":"迈威生物（688062）11月5日主力资金净卖出202.65万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681817308","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681817308?lang=zh_cn&edition=full","pubTime":"2026-11-06 08:20","pubTimestamp":1793924411,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月5日收盘，迈威生物报收于22.67元，上涨5.29%，换手率2.13%，成交量8.5万手，成交额1.91亿元。近5日资金流向一览见下表：迈威生物融资融券信息显示，融资方面，当日融资买入1283.68万元，融资偿还1061.09万元，融资净买入222.59万元。迈威生物主营业务：研发、生产以及销售创新型药物和生物类似药,以高效创新研发和产业化能力为支撑,通过治疗用生物制品的市场推广和销售获得商业利润。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110600008374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688062","02493","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677903107","title":"迈威生物（688062）10月23日主力资金净卖出680.54万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677903107","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677903107?lang=zh_cn&edition=full","pubTime":"2026-10-24 08:20","pubTimestamp":1792801207,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月23日收盘，迈威生物报收于22.82元，上涨4.73%，换手率4.17%，成交量9.61万手，成交额2.1亿元。近5日资金流向一览见下表：迈威生物融资融券信息显示，融资方面，当日融资买入872.98万元，融资偿还1185.03万元，融资净偿还312.05万元。迈威生物主营业务：研发、生产以及销售创新型药物和生物类似药,以高效创新研发和产业化能力为支撑,通过治疗用生物制品的市场推广和销售获得商业利润。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102400006897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","BK0239","688062","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676665504","title":"迈威生物（688062）披露9MW2821在ESMO大会以口头报告形式公布II期临床数据，10月19日股价上涨1.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2676665504","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676665504?lang=zh_cn&edition=full","pubTime":"2026-10-19 17:26","pubTimestamp":1792402016,"startTime":"0","endTime":"0","summary":"截至2026年10月19日收盘，迈威生物报收于22.56元，较前一交易日上涨1.21%，最新总市值为100.78亿元。迈威生物于近日自愿披露关于9MW2821在2026年欧洲肿瘤内科学会以口头报告形式报告临床数据的公告。公告显示，公司自主研发的靶向Nectin-4的ADC药物9MW2821，在2026年欧洲肿瘤内科学会大会上以口头报告形式公布针对既往接受过以拓扑异构酶I抑制剂为载荷的ADC治疗的局部晚期或转移性三阴性乳腺癌患者的II期临床研究数据。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101900022278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","688062","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676321502","title":"近两千亿解禁潮：首发股东浮盈翻倍，定增机构普遍亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=2676321502","media":"东方财富网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2676321502?lang=zh_cn&edition=full","pubTime":"2026-10-19 17:12","pubTimestamp":1792401171,"startTime":"0","endTime":"0","summary":"10月最后两周，A股将迎来1976.2亿元的限售股解禁，涉及71家公司。其中本周（10月19日至23日）解禁市值约952.83亿元、44家公司，下周（10月26日至30日）约1023.32亿元、28家公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"east_money_stock","url":"http://finance.eastmoney.com/news/1354,202610193899975575.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/1354,202610193899975575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"east_money_stock","symbols":["300848","BK0251","301513","301599","BK0026","001312","301387","600459","601026","BK0229","LU1146622755.USD","603477","301517","SGXZ49509284.SGD","603175","BK0240","002230","688759","BK0047","LU2580892862.HKD","LU1820825898.SGD","BK0127","LU2580892789.USD","688062","BK0035","BK0259","BK0231","603193","000881","688146","688820","BK0133","BK0182","688352","001386","600479","688765","BK0188","300782","BK0129","BK0239","603667","BK0028","688368","BK0109","BK0089","BK0077","688808","BK0017","688783"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675395401","title":"迈威生物（688062）10月13日主力资金净卖出775.58万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675395401","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675395401?lang=zh_cn&edition=full","pubTime":"2026-10-14 08:23","pubTimestamp":1791937435,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，迈威生物报收于22.94元，下跌4.5%，换手率3.02%，成交量6.96万手，成交额1.61亿元。近5日资金流向一览见下表：迈威生物融资融券信息显示，融资方面，当日融资买入622.01万元，融资偿还2104.87万元，融资净偿还1482.87万元。迈威生物主营业务：研发、生产以及销售创新型药物和生物类似药,以高效创新研发和产业化能力为支撑,通过治疗用生物制品的市场推广和销售获得商业利润。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400007126.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","BK1161","BK0239","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674889544","title":"迈威生物（688062）10月8日主力资金净买入221.75万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674889544","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674889544?lang=zh_cn&edition=full","pubTime":"2026-10-09 08:26","pubTimestamp":1791505568,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月8日收盘，迈威生物报收于24.33元，下跌10.02%，换手率5.83%，成交量13.41万手，成交额3.35亿元。近5日资金流向一览见下表：迈威生物融资融券信息显示，融资方面，当日融资买入1932.52万元，融资偿还1397.44万元，融资净买入535.09万元。迈威生物主营业务：研发、生产以及销售创新型药物和生物类似药,以高效创新研发和产业化能力为支撑,通过治疗用生物制品的市场推广和销售获得商业利润。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900006082.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","688062","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670535702","title":"迈威生物(688062.SH)子公司联威创元拟引入投资人 旨在推动创新药业务发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2670535702","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670535702?lang=zh_cn&edition=full","pubTime":"2026-09-28 22:02","pubTimestamp":1790604163,"startTime":"0","endTime":"0","summary":"上述增资均完成后，联威创元注册资本将由人民币8,260万元增加至人民币1.16亿元，公司预计仍持有联威创元71.21%股权，联威创元为公司合并报表范围内控股子公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1501738.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","688062","159992","02493","IBBQ","MEDX","BK1574","LNGR","06978","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670239730","title":"迈威生物：拟向联威创元增资8.25亿元并转让TCE项目资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2670239730","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670239730?lang=zh_cn&edition=full","pubTime":"2026-09-28 19:00","pubTimestamp":1790593246,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664585745","title":"迈威生物（688062）披露将参加科创板2026年半年度创新药行业集体业绩说明会，9月1日股价下跌1.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664585745","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664585745?lang=zh_cn&edition=full","pubTime":"2026-09-01 22:51","pubTimestamp":1788274270,"startTime":"0","endTime":"0","summary":"截至2026年9月1日收盘，迈威生物报收于27.87元，较前一交易日下跌1.62%，最新总市值为124.5亿元。该股当日开盘28.29元，最高28.5元，最低27.61元，成交额达1.54亿元，换手率为2.4%。近日，迈威（上海）生物科技股份有限公司披露公告，公司将于2026年9月16日15:00-17:00参加由上海证券交易所主办的科创板2026年半年度创新药行业集体业绩说明会，通过上证路演中心网络互动方式，就公司2026年半年度经营成果、财务状况等与投资者进行交流。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100043345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","BK1161","159992","688062","02493","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664885260","title":"迈威生物（688062）2026年中报简析：营收上升亏损收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=2664885260","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664885260?lang=zh_cn&edition=full","pubTime":"2026-09-01 06:09","pubTimestamp":1788214142,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期迈威生物发布2026年中报。根据财报显示，迈威生物营收上升亏损收窄。财报体检工具显示：建议关注公司现金流状况建议关注公司债务状况建议关注财务费用状况建议关注公司应收账款状况持有迈威生物最多的基金为中航优选领航混合发起A，目前规模为0.62亿元，最新净值1.6138，较上一交易日下跌1.06%，近一年下跌20.1%。本文数据来源于迈威生物2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100004792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688062","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663904946","title":"迈威生物(688062)6月30日股东户数1.85万户，较上期减少2.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663904946","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663904946?lang=zh_cn&edition=full","pubTime":"2026-08-30 17:07","pubTimestamp":1788080860,"startTime":"0","endTime":"0","summary":"证券之星消息，近日迈威生物披露，截至2026年6月30日公司股东户数为1.85万户，较3月31日减少523.0户，减幅为2.76%。在化学制药行业个股中，迈威生物股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.67万户。从股价来看，2026年3月31日至2026年6月30日，迈威生物区间跌幅为21.55%，在此期间股东户数减少523.0户，减幅为2.76%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000011095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688062","BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658969219","title":"港股午评|恒生指数早盘跌0.63% CRO概念继续走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2658969219","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658969219?lang=zh_cn&edition=full","pubTime":"2026-08-11 12:00","pubTimestamp":1786420834,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数跌0.63%，跌163点，报25773点；恒生科技指数跌1.27%。港股早盘成交1158亿港元。药明康德司法取得进展，有利于CXO公司在海外争取新的订单。再鼎医药涨超5%，Q2产品收入环比增长11%，花旗看好中国业务下半年企稳。津上机床中国涨超5%，电子与AI液冷两大领域在新订单占比约四成。黄金股普遍承压。油价走高加剧通胀上行担忧，美联储鹰派释放强硬信号。中国黄金国际跌2.5%；紫金矿业跌3.5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478385.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1831875114.USD","LU0737861772.HKD","BK1587","LU2097828805.USD","LU1769817179.HKD","002821","LU0106252389.USD","JINFF","688062","LU0868486357.SGD","LU0828237510.HKD","LU2264538146.SGD","HK0000306685.HKD","LU0348814723.USD","02631","LU1504937902.USD","LU1242518931.SGD","LU2097828631.EUR","03115","ZLAB","06821","SG9999002463.SGD","BK1505","02493","LU0572944931.SGD","BK1169","HSI","LU0096374516.USD","03033","09088","LU0269904917.USD","01548","03032","LU1719994722.HKD","BK1594","LU0164880469.USD","03423","ZIJMY","LU2097828714.EUR","LU0211977185.USD","LU0345780281.USD","09688","LU2226246903.HKD","LU0456854461.SGD","LU0329678170.USD","06616","LU0417516902.SGD","LU0082770016.USD","03088","LU0039217434.USD","LU0871576103.HKD","LU1988902786.USD","LU2460026573.USD","LU1282648689.USD","07200","LU0431992006.USD","LU0164865239.USD","LU0797268264.HKD","03037","LU0345780521.USD","LU0165289439.USD","LU1720050803.USD","SG9999004220.SGD","HK0000320223.HKD","LU0181495838.USD","LU0828237940.HKD","LU0620787316.HKD","BK1574","BK1544","LU0278937759.USD","MCHmain","LU0417516738.SGD","IE0032431581.USD","LU0173614495.USD","688234","LU0828238088.HKD","LU0244354667.USD","300759","BK1588","LU2008162690.USD","LU2399975544.HKD","82800","LU0348827113.USD","03419","LU0918141887.USD","LU0821914370.USD","BK1141","BK1592","01541","03417","LU0274383008.USD","LU2097828557.USD","BK1583","LU1808992512.USD","LU0348766576.USD","LU0918141705.HKD","601899","LU0106959298.USD","BK1183","LU1769817096.USD","LU0049853897.USD","LU0540923850.HKD","02837","03759","LU1242518857.USD","LU0287142896.SGD","LU2488822045.USD","LU1481107354.HKD","LU0048580855.USD","LU0061477393.USD","LU0307460666.USD","BK1190","02800","BK1170","07500","LU0588546209.SGD","09115","BK1576","LU0531971595.HKD","LU2177674079.SGD","09067","LU1105468828.SGD","02899","LU0634319403.HKD","LU0561508036.HKD","03067","LU0326950275.SGD","LU0370786039.SGD","LU0348816934.USD","LU1961090484.USD","HHImain","07552","LU0348767384.USD","LU0348735423.USD","LU0979878070.USD","LU0228659784.USD","02833","LU0737861699.HKD","513600","LU0463099449.HKD","LU0886674414.USD","02099","LU0266512473.USD","07226","LU0469268626.HKD","BK1161","LU1251922891.USD","BK1198","LU0149721374.USD","LU0266512127.USD","HK0000320264.USD","LU1188198961.HKD","LU2097828474.EUR","01651","02026","BK1129","LU0327786744.USD","LU1064131342.USD","LU1794554557.SGD","PONY","LU0043850808.USD","83115","SG9999001093.SGD","BK1191","HSTECH","LU1048596156.SGD","LU1303224171.USD","LU0509642566.USD","BK1109","LU0164939612.USD","07300","LU0140636845.USD","LU0329678337.USD","LU0348825331.USD","SG9999003461.SGD","06951","LU0328353924.USD","300408","LU0082770016.SGD","LU3063872942.SGD","LU2039709279.SGD","HK0000306701.USD","LU1770034418.SGD","LU1224709979.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656165213","title":"每周股票复盘：迈威生物（688062）9MW5211注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2656165213","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656165213?lang=zh_cn&edition=full","pubTime":"2026-08-02 01:46","pubTimestamp":1785606376,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，迈威生物报收于28.68元，较上周的31.09元下跌7.75%。本周，迈威生物7月27日盘中最高价报32.64元。迈威生物当前最新总市值128.12亿元，在化学制药板块市值排名35/149，在两市A股市值排名1397/5202。公司公告汇总迈威生物自愿披露关于9MW5211注射液临床试验申请获得国家药品监督管理局批准的公告。9MW5211注射液用于原发性胆汁性胆管炎适应症的临床试验申请已获批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200000348.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688062","02493","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132577846","title":"迈威生物-U：9MW5211注射液临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1132577846","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132577846?lang=zh_cn&edition=full","pubTime":"2026-07-31 20:36","pubTimestamp":1785501414,"startTime":"0","endTime":"0","summary":"北京时间7月31日消息——迈威生物（上海）生物科技股份有限公司（688062.SS）正式对外披露，其自主研发的9MW5211注射液已获得国家药品监督管理局（NMPA）的临床试验申请批准。这一进展标志着该候选药物正式迈入临床试验阶段，有望为相关疾病领域带来新的治疗选择。\n","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103867558","title":"迈威生物-U：9MW5211注射液临床试验申请获NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1103867558","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103867558?lang=zh_cn&edition=full","pubTime":"2026-07-31 20:12","pubTimestamp":1785499955,"startTime":"0","endTime":"0","summary":"迈威生物（上海）生物科技股份有限公司宣布，其研发的9MW5211注射液已获得国家药品监督管理局（NMPA）的临床试验批准通知书。这一进展标志着该候选药物正式进入临床开发阶段，为后续研究铺平了道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652237484","title":"每周股票复盘：迈威生物（688062）9MW5211注射液获准开展白癜风临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2652237484","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652237484?lang=zh_cn&edition=full","pubTime":"2026-07-19 01:35","pubTimestamp":1784396110,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘，迈威生物报收于31.0元，较上周的31.87元下跌2.73%。本周，迈威生物7月16日盘中最高价报36.0元。此前，该药品用于炎症性肠病、多发性硬化和1型糖尿病适应症的临床试验申请已获国家药监局批准，其中IBD适应症还获得FDA许可。9MW5211为全球首个靶向该分子的临床阶段候选药物，临床前研究显示其在多种自身免疫疾病模型中具有显著治疗潜力，且安全性良好。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900000285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0239","688062","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123562061","title":"迈威生物-U新药9MW5211注射液临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1123562061","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123562061?lang=zh_cn&edition=full","pubTime":"2026-07-15 20:03","pubTimestamp":1784117023,"startTime":"0","endTime":"0","summary":"迈威生物（上海）股份有限公司宣布，其研发的9MW5211注射液的临床试验申请，已正式获得国家药品监督管理局的批准。\n这一进展标志着公司的一款在研新药向临床开发阶段迈出了关键一步。9MW5211注射液是迈威生物管线中的重要候选药物，其获批开展临床试验，为后续的研发进程奠定了基础。\n公司后续将按照国家相关法律法规和要求，积极开展该药物的临床试验工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688062","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650115423","title":"每周股票复盘：迈威生物（688062）9MW5211注射液获批T1DM临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2650115423","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650115423?lang=zh_cn&edition=full","pubTime":"2026-07-12 02:49","pubTimestamp":1783795748,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，迈威生物报收于31.87元，较上周的32.06元下跌0.59%。本周关注点公司公告汇总：9MW5211注射液用于1型糖尿病适应症的临床试验申请获国家药监局批准公司公告汇总：该药品此前已获批用于炎症性肠病和多发性硬化适应症的临床试验公司公告汇总：9MW5211注射液针对多种自身免疫性疾病核心病理机制，具高度特异性公司公告汇总迈威生物自愿披露关于9MW5211注射液临床试验申请获得国家药品监督管理局批准的公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000973.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02493","688062","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198547368","title":"迈威生物-U新药9MW5211注射液临床试验申请获国家药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1198547368","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198547368?lang=zh_cn&edition=full","pubTime":"2026-07-07 21:16","pubTimestamp":1783430197,"startTime":"0","endTime":"0","summary":"迈威生物-U (688062) 宣布，其研发的9MW5211注射液临床试验申请已获得中国国家药品监督管理局的正式批准。\n这一进展标志着该创新药物将进入临床开发阶段，为后续的疗效与安全性评估铺平了道路。公司致力于推进其生物制药产品管线，此次获批是其研发进程中的重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688062"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649987609","title":"迈威生物(688062.SH)：9MW5211注射液临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2649987609","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649987609?lang=zh_cn&edition=full","pubTime":"2026-07-07 20:15","pubTimestamp":1783426507,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迈威生物 发布公告，近日，公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，9MW5211注射液用于1型糖尿病适应症的临床试验申请获得批准，此前，其用于炎症性肠病适应症的临床试验申请已分别获得国家药品监督管理局批准和FDA许可，用于多发性硬化适应症的临床试验申请已获得国家药品监督管理局批准。通过选择性识别并清除这群致病性细胞，9MW5211可有效阻断免疫级联反应，进而缓解疾病进展并改善临床症状。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464336.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BMED","BK0239","IBBQ","688062","02493"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1794028705801,"stockEarnings":[{"period":"1week","weight":0.1023},{"period":"1month","weight":-0.1834},{"period":"3month","weight":-0.2763},{"period":"6month","weight":-0.372},{"period":"1year","weight":-0.5035},{"period":"ytd","weight":-0.426}],"compareEarnings":[{"period":"1week","weight":0.0139},{"period":"1month","weight":-0.0502},{"period":"3month","weight":-0.0738},{"period":"6month","weight":-0.127},{"period":"1year","weight":-0.0895},{"period":"ytd","weight":-0.0805}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"迈威(上海)生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"18554人(较上一季度增加0.54%)","perCapita":"21537股","listingDate":"2022-01-18","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路230号2幢105室","registeredCapital":"44673万元","survey":" 迈威(上海)生物科技股份有限公司的主营业务是研发、生产以及销售创新型药物和生物类似药。公司的主要产品是抗体、ADC药物、重组蛋白、小分子化学药。截至本报告披露日，公司拥有15个处于临床研究或上市阶段的重点品种，其中4个产品已获批上市，1个品种在境内生产药品注册上市许可申请审评中；2026年以来，共有3个品种获得国内外9项临床试验准入。","listedPrice":34.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迈威生物-U(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迈威生物-U(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迈威生物-U,688062,迈威生物-U股票,迈威生物-U股票老虎,迈威生物-U股票老虎国际,迈威生物-U行情,迈威生物-U股票行情,迈威生物-U股价,迈威生物-U股市,迈威生物-U股票价格,迈威生物-U股票交易,迈威生物-U股票购买,迈威生物-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迈威生物-U(688062)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迈威生物-U(688062)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}